DaVita Inc.
DVA
주식 순위
#1790
DaVita Inc. specializes in delivering essential kidney dialysis treatments and... DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
주가
$187.20
마지막 동기화: 2026-10-19
시가총액
$11.94B
변동 (1일)
0.21%
변동 (1년)
46.19%
국가
US
거래 DaVita Inc. (DVA)
카테고리
Healthcare
DaVita Inc. (DVA)의 P/E 비율
October 2026 기준 P/E 비율 TTM: 15.54
DaVita Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 15.54입니다. 2024년 말 기준 P/E 비율은 13.57였습니다.
DaVita Inc.의 P/E 비율 기록 (2000 ~ 2026)
매년 말 P/E 비율
| 연도 | P/E 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 15.54 | 15.69% |
| 2025 | 13.43 | -1.10% |
| 2024 | 13.57 | -1.30% |
| 2023 | 13.75 | 11.00% |
| 2022 | 12.39 | 1.28% |
| 2021 | 12.23 | -32.70% |
| 2020 | 18.18 | 28.28% |
| 2019 | 14.17 | -74.30% |
| 2018 | 55.14 | 168.49% |
| 2017 | 20.54 | 39.58% |
| 2016 | 14.71 | -73.13% |
| 2015 | 54.76 | 146.24% |
| 2014 | 22.24 | 5.88% |
| 2013 | 21.00 | 6.08% |
| 2012 | 19.80 | 31.89% |
| 2011 | 15.01 | -13.66% |
| 2010 | 17.39 | 20.76% |
| 2009 | 14.40 | 3.35% |
| 2008 | 13.93 | -10.87% |
| 2007 | 15.63 | -23.10% |
| 2006 | 20.33 | -8.92% |
| 2005 | 22.32 | 27.09% |
| 2004 | 17.56 | 25.84% |
| 2003 | 13.95 | 23.89% |
| 2002 | 11.26 | -24.48% |
| 2001 | 14.92 | -85.60% |
| 2000 | 103.60 | 0.00% |
유사 기업 또는 경쟁사의 P/E 비율
| 회사 | P/E 비율 | P/E 비율 차이 | 국가 |
|---|---|---|---|
| 15.70 | 1.06% |
US
|
|
| - | - |
DE
|
|
| 10.40 | -33.08% |
US
|
|
| 32.07 | 106.40% |
SA
|
|
| 20.00 | 28.72% |
BR
|
P/E 비율 읽는 방법
P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.
P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.
양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.